Moderna’s COVID Vaccine Candidate is Almost 95% Effective

These results were based on 95 patients with confirmed COVID infections, and 5 of these got the vaccine candidate.

Published
These results were based on 95 patients with confirmed COVID infections - 90 patients received the placebo and 5 patients got the vaccine
i

On Monday, 16 November, US’ Moderna joined in the COVID-19 vaccine race by revealing their impressive phase 3 trial results as their vaccine candidate was found to be 94.5% effective.

These results were based on 95 patients with confirmed COVID infections - 90 patients received the placebo and 5 patients got the vaccine reported The Guardian. However, the study enrolled more than 30,000 participants in the US.

Moderna planned to ask the US’ Food and Drug Regulator for emergency-use authorisation.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.”
Stephane Bancel, Moderna’s CEO.

Bancel said that what was most promising is that two other companies announced similar results, reported LiveMint.

Recently, Pfizer and BioNTech announced on Monday, 9 November that their coronavirus vaccine was more than 90% effective in preventing COVID-19. On Wednesday, 11 November, Russia’s sovereign wealth fund announced that its Sputnik V vaccine is 92 per cent effective at protecting people from COVID-19 according to interim trial results.

It must be noted that this is all still very early data, and more trials are needed to determine safety and efficacy.

Like the Pfizer vaccine, Moderna too uses mRNA.

Dr Shahid Jameel, Virologist and Director, Trivedi School of Biosciences at Ashoka University, when talking about Pzifer and mRna said,

“This bodes really well for the future because it’s fairly simple to make RNA vaccines once you have the platform available.This also proves that you can take a small part of the virus structure, immunise with it and get protection. In this case, they didn’t even have to use the entire spike protein, but only a part of the spike protein.So yes, it is optimistic from many different angles.”
Dr Shahid Jameel, Virologist

In the Moderna vaccine, out of the 95 patients with COVID, 15 were adults aged 65 or over, and 20 were from diverse communities including 12 people who identified as Hispanic, 4 Black Americans, 3 Asian Americans and 1 person who was multiracial.

Read more about the vaccine candidates in the running here.

(With inputs from The Guardian and LiveMint)

(Subscribe to FIT on Telegram)

Stay Up On Your Health

Subscribe To Our Daily Newsletter Now.

Join over 120,000 subscribers!